Nano Holdings, Inc. (FRA:3NQ)

Germany · Delayed Price · Currency is EUR

0.5100

-0.0200 (-3.77%)

Last updated: Jun 26, 2026, 5:15 PM CET

-36.25% (1Y)

Market Cap	43.32M -22.4%
Revenue (ttm)	949.09K +61.1%
Net Income	-5.14M
EPS	-0.07
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.5100
Previous Close	0.5300
Day's Range	0.5100 - 0.5100
52-Week Range	0.5050 - 1.1500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Nano Holdings

Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material. The company was formerly known as NANO MRNA Co.,Ltd. and changed its name to Nano Holdings,... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 1996

Employees 20

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 3NQ

Financial Performance

In fiscal year 2026, Nano Holdings's revenue was 174.00 million, an increase of 61.11% compared to the previous year's 108.00 million. Losses were -943.00 million, 12.9% more than in 2025.

Financial numbers in JPY Financial Statements